Table 3.
Change of C-reactive protein concentration and erythrocyte sedimentation rate during induction phase after IPF therapy
| Parameter | Weeks after IPF therapy | p value (ANOVA) | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | ||
| Number of patients | 13 | 13 | 13 | 10 | 7 | 8 | 13 | |
| CRP, mg/dL, mean (SD)a | 9.42 (8.29) | 0.61 (0.67) | 0.11 (0.17) | 0.09 (0.16) | 0.04 (0.04) | 0.28 (0.54) | 0.33 (0.65) | < 0.0001 |
| Erythrocyte sedimentation rate, mm/h, mean (SD)b | 59 (20) | 37 (13) | 25 (14) | 17 (14) | 26 (21) | 18 (14) | 17 (14) | < 0.0001 |
a Reference range ≤ 0.3 mg/dL.
b Reference range ≤ 10 mm/h for male patients; ≤ 15 mm/h for female patients.
ANOVA = analysis of variance; CRP = C-reactive protein; IPF therapy = infliximab and plant-based diet as the first-line therapy; SD = standard deviation.